Finerenone shows significant benefits in patients with kidney disease and type 1 diabetes, which could lead to the first ...
Bitter taste receptors inside cancer cells have been found to be activated in the presence of anti-cancer drugs. Shutting ...
The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented in-person at American Society of Nephrology Kidney Week 2025 November 5–9.
Type 1 diabetes with CKD is understudied with no advancement of therapy options since the 1990s. The FINE-ONE phase 3 trial addresses a high, unmet need for treatments.
Experiments in three therapeutic cancer vaccine mouse models, conducted by investigators at the Vaccine Branch of the National Cancer Institute in Bethesda, Maryland, support the conclusion that ...
Key Results from Clinical Study of NG101 for Semaglutide-Induced Nausea and Vomiting ...
Two open-label extension studies show that the FcRn blocker nipocalimab has durable efficacy and sustained symptom control ...
Insilico announced the launch of its innovative cardiometabolic disease portfolio at BIO Europe 2025. The portfolio covers a ...
Even though nearly all women—approximately 85%—report experiencing menopause symptoms, science has offered very few solutions ...
Q3 2025 Earnings Call Transcript November 4, 2025 Corcept Therapeutics Incorporated misses on earnings expectations. Reported EPS is $0.16 EPS, expectations were $0.18. Operator: Thank you for ...
New analysis confirms reductions in blood pressure and albuminuria by aprocitentan in patients with true resistant hypertension and high ...
The MarketWatch News Department was not involved in the creation of this content.-- VYVGART(R) SC is first and only neonatal Fc receptor blocker approved to treat CIDP -- Authoriz ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback